Children’s Health Defense Demands FDA Withdraw Approval of Remdesivir for Children

Children’s Health Defense Demands FDA Withdraw Approval of Remdesivir for Children


Children’s Health Defense demanded that the Food and Drug Administration (FDA) withdraw its approval of the antiviral drug remdesivir for children.

Dr. Madhava Setty, senior science editor for CHD’s Defender newsletter, cited 72 percent of children hospitalized with COVID-19 who “suffered adverse events” as a reason why remdesivir should not be approved.

Children’s Health Defense demands FDA withdraw its approval of Remdesivir for infants and children, citing 72% adverse events rate https://t.co/ukD524ruHU

— ꧁✬Hυ𝓵ᵃ𝔥卂ᶰ𝓭ѕ✬꧂ (@ThehulaG) May 4, 2022

Trending: Western Weapons in Ukraine Being Sold On via Encrypted Messaging App: Report

The Defender noted from the clinical study results:

According to the press release, the FDA’s decision to approve the therapy, marketed under the name Veklury, is supported by a clinical study conducted on infants 4 weeks and older weighing a minimum of 6.6 pounds.

The study is underway and will not be completed

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend